Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O 6-methylguanine-DNA methyltransferase P140K

Gene Therapy

Volumn 17, Issue 3, 2010, Pages 389-399

  Maier, P ^a,b   Spier, I ^a   Laufs, S ^a   Veldwijk, M R ^a,b   Fruehauf, S ^c   Wenz, F ^b   Zeller, W J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Paracelsus Klinik   (Germany)

Author keywords

Chemoprotection; Hematopoietic stem cells; Lentiviral vector; MDR1; MGMTP140K

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; CD34 ANTIGEN; DOXORUBICIN; LENTIVIRUS VECTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; NIMUSTINE; PACLITAXEL; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER RESISTANCE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TUMOR GENE;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOPROTECTION; DACARBAZINE; DOXORUBICIN; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; LENTIVIRUS; NIMUSTINE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; P-GLYCOPROTEIN; PACLITAXEL;

EID: 77949424638     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.133     Document Type: Article

References (59)

1. 6- benzylguanine plus BCNU. Blood 1996; 88: 1649-1655.
2. Fruehauf S, Breems DA, Knaan-Shanzer S, Brouwer KB, Haas R, Lowenberg B et al. Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum Gene Ther 1996; 7: 1219-1231.
3. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-2458.
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
5. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hemato-poietic stem cells. Cell 1991; 66: 85-94.
6. Schiedlmeier B, Schilz AJ, Kuhlcke K, Laufs S, Baum C, Zeller WJ et al. Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum Gene Ther 2002; 13: 233-242.
7. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev 2002; 2: 431-441.
8. Takahashi S, Ito Y, Hatake K, Sugimoto Y. Gene therapy for breast cancer. Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital. Breast Cancer (Tokyo, Japan) 2006; 13: 8-15.
9. Becker PS, Yu YP, Ceredona AM, Walsh WV, O'Donnell JL, Baum C et al. Transfer of the multidrug resistance gene, MDR-1, to hematopoietic progenitors from a patient with transformed large cell lymphoma, and demonstration of in vivo chemotherapy protection with dose escalating chemotherapy. Blood 2004; 104: 5278.
10. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165-172.
11. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-6129.
12. Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-linking and mono-adduct repair in nitrosourea-treated human tumour cells. Nature 1980; 288: 727-729.
13. 6- benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 1996; 35: 1328-1334.
14. 6- benzylgua-nine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990; 87: 5368-5372.
15. 6-benzylguanine in humans: metabolic, pharmaco-kinetic, and pharmacodynamic findings. J Clin Oncol 1998; 16: 1803-1810.
16. Zeller WJ, Berger MR, Henne T, Weber E. More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1- nitrosourea in the rat. Cancer Res 1986; 46: 1714-1716.
17. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000; 18: 3522-3528.
18. 6-alkylguanine-DNA-alkyltransfer-ase. Clin Cancer Res 1996; 2: 1129-1134.
19. 6-benzylguanine. Cancer Res 1994; 54: 6221-6227.
20. 6-benzylguanine. Cancer Res 1998; 58: 1936-1945.
21. 6-alkylating agents and retro-viral backbones. Eur J Haematol 2001; 67: 2-13.
22. 6-benzylguanine and 1,3-bis(2-chlor-oethyl)-nitrosourea or temozolomide. Hum Gene Ther 2004; 15: 758-769.
23. Zielske SP, Gerson SL. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther 2002; 5: 381-387.
24. 6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Mol Cancer Ther 2003; 2: 1321-1329.
25. Pollok KE, Hartwell JR, Braber A, Cooper RJ, Jansen M, Ragg S et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 2003; 14: 1703-1714.
26. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005; 105: 997-1002.
27. Suzuki M, Sugimoto Y, Tsukahara S, Okochi E, Gottesman MM, Tsuruo T. Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy. Clin Cancer Res 1997; 3: 947-954.
28. 6-alkylguanine-DNA-alkyltransfer-ase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Therapy 1999; 6: 1489-1493.
29. Wang J, Chen Z, Xia X, Lu D, Xue J, Ruan C. Improvement of combination chemotherapy tolerance by introduction of poly-cistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells. Leuk Res 2002; 26: 281-288.
30. 6-methylguanine-DNA-methyl transferase. J Gene Med 2006; 8: 972-979.
31. Scherr M, Battmer K, Blomer U, Schiedlmeier B, Ganser A, Grez M et al. Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 2002; 99: 709-712.
32. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
33. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
34. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000; 1: 376-382.
35. Wong ET, Ngoi SM, Lee CG. Improved co-expression of multiple genes in vectors containing internal ribosome entry sites (IRESes) from human genes. Gene Therapy 2002; 9: 337-344.
36. Ferlini C, Distefano M, Pierelli L, Bonanno G, Fattorossi A, Battaglia A et al. A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development. Pharmacol Toxicol 2001; 89: 231-236.
37. Fruehauf S, Haas R, Zeller WJ, Hunstein W. CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors. Stem Cells 1994; 12: 95-102.
38. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
39. Postmus PE. Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest 1998; 113: 28S-31S.
40. Azzabi A, Hughes AN, Calvert PM, Plummer ER, Todd R, Griffin MJ et al. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. Br J Cancer 2005; 92: 1006-1012.
41. Chamberlain MC, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995; 13: 2066-2071.
42. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
43. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
44. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
45. Laufs S, Nagy KZ, Giordano FA, Hotz-Wagenblatt A, Zeller WJ, Fruehauf S. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. Mol Ther 2004; 10: 874-881.
46. Laufs S, Guenechea G, Gonzalez-Murillo A, Zsuzsanna Nagy K, Luz Lozano M, del Val C et al. Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med 2006; 8: 1197-1207.
47. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
48. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
49. Schambach A, Baum C. Clinical application of lentiviral vectors\concepts and practice. Curr Gene Ther 2008; 8: 474-482.
50. 6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 2006; 13: 391-400.
51. Bozorgmehr F, Laufs S, Sellers SE, Roeder I, Zeller WJ, Dunbar CE et al. No evidence of clonal dominance in primates up to four years following transplantation of multidrug resistance 1 retro-virally transduced long-term repopulating cells. Stem Cells 2007; 25: 2610-2618.
52. Kohn DB, Candotti F. Gene therapy fulfilling its promise. N Engl J Med 2009; 360: 518-521.
53. Chinnasamy D, Milsom MD, Shaffer J, Neuenfeldt J, Shaaban AF, Margison GP et al. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J 2006; 3: 14.
54. Santoni de Sio FR, Gritti A, Cascio P, Neri M, Sampaolesi M, Galli C et al. Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells 2008; 26: 2142-2152.
55. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, NY) 2003; 302: 415-419.
56. Knipper R, Kuehlcke K, Schiedlmeier B, Hildinger M, Lindemann C, Schilz AJ et al. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Therapy 2001; 8: 239-246.
57. Maier P, Herskind C, Fleckenstein K, Spier I, Laufs S, Zeller WJ et al. MDR1 gene transfer using a lentiviral SIN vector confers radioprotection to human CD34(+) hematopoietic progenitor cells. Radiation Res 2008; 169: 301-310.
58. Schiedlmeier B, Kuhlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 2000; 95: 1237-1248.
59. 6-alkylguanine-DNA-alkyltransferase measured by flow cyto-metric analysis in blood and bone marrow mononuclear cells. Clin Cancer Res 1998; 4: 475-481.